Device promotion oversight could be placed solely with FTC, advertising group says.
This article was originally published in The Gray Sheet
DEVICE, DRUG PROMOTIONAL ACTIVITIES REGULATION EXCLUSIVELY BY FTC is proposed by the American Association of Advertising Agencies (AAAA) in its legislative proposal to reform FDA's device and drug marketing and communications regulations. Congress "could grant FTC exclusive jurisdiction to regulate marketing of prescription drugs and devices where the FDA and FTC now have concurrent and overlapping jurisdictions," the association says, as "one way to accomplish both substantive and procedural reform."
You may also be interested in...
Sandoz Canada has become the first manufacturer to launch generic versions of posaconazole and silodosin in Canada. The company launched the generic version of Allergan’s Rapaflo (silodosin) after a Canadian court ruled that Sandoz did not infringe a key formulation patent.
US healthcare insurance provider Health Net failed to respect Amarin’s patent rights in the way it distributed Hikma’s generic version of Vascepa (icosapent ethyl), the originator contends in an expanded induced infringement suit.
Netherlands' Authority for Consumers and Markets has reprimanded a dietary supplements player for purchasing fake followers and likes on social media to exaggerate the popularity of its products. It is the first case of its kind in the country.